Nanotechnology consumer survey states over 70% of users are worried about public touchscreens
DUBLIN, IRELAND, AUGUST 19, 2019 – Touchscreens are an essential part of everyday, modern life. When there are four times as many germs found on a self-service touchscreen than on a toilet seat, it’s no surprise to learn that many of us are concerned about engaging with surfaces, and being exposed to infectious germs such as MRSA, E. coli and C. diff.
In a recent consumer survey from nano-technology company Kastus, over 70% of respondents stated they were worried about using public touchscreens. Bank ATMs caused the most concern amongst respondents, with doctor’s surgery and hospital check in screens a close second. Fast food chain order screens, supermarket self-service tills and airport check-in kiosks were also identified as a concern.
With the World Health Organisation stating that antimicrobial resistance is a serious threat to global health, the world is looking to manufacturers to help control the situation, calling for touchscreen and smartphone businesses to introduce an environmentally friendly, scientifically proven solution that will help keep touchscreen surfaces germ-free.
Parents also raised concerns over other touchscreens including mobile phones and tablets. Smartphones, carry 10 times more bacteria than most toilet seats, yet an alarming 65% of people surveyed admitted to never cleaning their mobile phone. Given that 90% of respondents with children under 12 regularly share their mobile with their child, phone screens are also a key area for manufacturers to address.
“Touchscreens and smartphones are an ideal surface for bacteria to reproduce due to the heat they emit, harboring all kinds of germs that can easily thrive in those conditions, said John Browne, founder and CEO of Kastus. “There is a scientifically proven solution that will help manufacturers protect against the spread of bacteria, we just need to do more to encourage the widespread use of it as it delivers a very real control measure in the fight against antimicrobial infections.”
A game-changing, always on, germ-free solution
Kastus® is on a mission to tackle the growing issue of antimicrobial resistance with its game-changing surface solution. A patented coating that’s applied during the glass manufacturing process, Kastus® Glass is scientifically proven to eliminate up to 99.99% of harmful bacteria including MRSA, E. coli and C. diff, delivering germ-free protection to touchscreens and personal devices, such as tablets and smartphones, for life.
Powered by their patented Kastus® Intelligent Surface Technology™, the invisible coating also transforms glass into a self-cleaning surface, reducing the need for chemical cleaners while providing germ-free protection. Once ‘baked in’ to the glass surface, the coating technology is incredibly durable, plus as it’s non-leaching it is also friendly to the environment.
To find out more about Kastus and this ground breaking technology visit www.kastus.com
Founded in 2014, Kastus is an award-winning Irish nano-technology company that offers a patented range of antimicrobial coatings designed to protect glass, ceramic and metal surfaces from harmful bacteria.
Kastus® uses a novel Photo-physical coating process fuelled by ambient air moisture and light, both unlimited fuel resources. The reactive oxygen species generated on surfaces by the patented process, effectively ‘bash’ the bacteria, disrupting its cell wall until it’s eliminated. The game changer here, is that bacteria cannot build up a resistance or immunity to Kastus coating technology and as the fuel source is unlimited, the protective antimicrobial power is ‘always on’ through the lifetime of the product.
Kastus works with Enterprise Ireland, the Irish State agency that partners with Irish enterprises to help them start, grow, innovate, and win export sales in global markets.
 Dr Charles Gerba, University of Arizona.
 Research conducted by Trend-Monitor in June 2019, with a representative sample of 1000 UK consumers
 Review of Antimicrobial Resistance commissioned by UK Prime Minister July 2014, performed by Jim O’Neill
 Research conducted by Lancet Infectious Disease Journal